With all enrolled patients receiving either the investigational treatment or the standard of care therapy, this study compares the efficacy of SY-1425 in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.

**Trial participant eligibility key criteria:**
- 18 years of age and older
- RARA-positive, based on the investigational assay
- Newly diagnosed with very high, high or intermediate risk MDS
- Have not received prior treatment for MDS

Contact your doctor to discuss participation in the SY-1425 trial. For more information about the SY-1425 trial visit ClinicalTrials.gov and search NCT04797780.

SY-1425 is an investigational agent and has not been approved by the FDA as a treatment for any indication.